Engineered DNA nanodrugs alleviate inflammation in inflammatory arthritis

This study demonstrates that an engineered DNA nanodrug (TD-P-dODN) enhances the efficacy of nucleic acid drugs and represents a promising strategy for RA treatment.Graphical abstractThe intracellular NF-κB pathway is activated in the inflamed synovium. The degradation of IκB results in the release of the P50/P65 complex that can translocate into the nucleus and initiate the transcription of inflammatory protein. TD-P-dODNs insert across the P50/P65 complex in cytoplasm and inhibit its downstream activities, which ultimately reduces inflammation in vitro and in vivo.
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research